United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 5

Name: Surgical And Medical Instruments And Apparatus Stocks in USA: Revenue Cohort 5 comparison snapshot
Creator: Fliar BI Prism

A five-company surgical and medical instruments and apparatus cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness

Readiness leaderOrthoPediatrics · 52

Strongest available pathLeMaitre Vascular · +40.7%

Widest latest marginLeMaitre Vascular · 23.1%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1KIDS · Nasdaq

OrthoPediatrics

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2006Wilmington$617.5M market cap

View full Companies Radar profile

52Moderate

Snapshot price$23.65as of page date

Monthly-close return-66.7%five-year window

FY2025 revenue$0.24BORTHOPEDIATRICS CORP

Net margin-16.8%FY2025

P/E snapshot-33.3xone ratio, not a verdict

Prism attention23.3%share across these five

Filing track recordRevenue, USD billions

+141.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 24.6%

52-week position75% through range

$14.42$26.74

News mentions948

Community mentions12partial coverage

U.S.-scope patents212

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal73/100
Management stability90/100
Market position14/100
Capital-event signal63/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 6 M&A involvements, 2 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2LMAT · Nasdaq

LeMaitre Vascular

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1983Burlington, Massachusetts$1.84B market cap

View full Companies Radar profile

44Cautious

Snapshot price$80.45as of page date

Monthly-close return+40.7%five-year window

FY2025 revenue$0.25BLEMAITRE VASCULAR INC

Net margin23.1%FY2025

P/E snapshot28.1xone ratio, not a verdict

Prism attention17.3%share across these five

Filing track recordRevenue, USD billions

+61.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.8%

52-week position5% through range

$78.27$118.0

News mentions704

Community mentions0partial coverage

U.S.-scope patents32

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal77/100
Management stability70/100
Market position20/100
Capital-event signal20/100
Innovation pulse5/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 8 M&A involvements, 8 asset-acquisition events and 12 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3SIBN · Nasdaq

Si-Bone

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2008San Jose, California$851.9M market cap

View full Companies Radar profile

43Cautious

Snapshot price$19.21as of page date

Monthly-close return-21.3%five-year window

FY2025 revenue$0.20BSI-BONE, Inc.

Net margin-9.4%FY2025

P/E snapshot-58.1xone ratio, not a verdict

Prism attention19.1%share across these five

Filing track recordRevenue, USD billions

+122.9%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.2%

52-week position74% through range

$11.48$21.89

News mentions777

Community mentions14partial coverage

U.S.-scope patents17

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal66/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4CERS · Nasdaq

Cerus

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1991Concord, California$534.0M market cap

View full Companies Radar profile

41Cautious

Snapshot price$2.65as of page date

Monthly-close return-57.8%five-year window

FY2025 revenue$0.23BCERUS CORP

Net margin-6.7%FY2025

P/E snapshot-530.0xone ratio, not a verdict

Prism attention26.7%share across these five

Filing track recordRevenue, USD billions

+46.6%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 10.0%

52-week position64% through range

$1.17$3.47

News mentions1.1K

Community mentions0partial coverage

U.S.-scope patents389

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal62/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TMCI · Nasdaq

Treace Medical Concepts

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2013Ponte Vedra Beach, Florida$302.4M market cap

View full Companies Radar profile

31Cautious

Snapshot price$4.65as of page date

Monthly-close return-81.8%five-year window

FY2025 revenue$0.21BTREACE MEDICAL CONCEPTS, INC.

Net margin-27.7%FY2025

P/E snapshot-5.5xone ratio, not a verdict

Prism attention13.6%share across these five

Filing track recordRevenue, USD billions

+125.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 22.5%

52-week position54% through range

$1.17$7.63

News mentions555

Community mentions0partial coverage

U.S.-scope patents426

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal26/100
Management stability90/100
Market position0/100
Capital-event signal34/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

LeMaitre Vascular

+40.7%

Si-Bone

-21.3%

Cerus

-57.8%

OrthoPediatrics

-66.7%

Treace Medical Concepts

-81.8%

Latest revenue

USD billions, official filing scope shown on each company card.

LeMaitre Vascular

$0.25B

OrthoPediatrics

$0.24B

Cerus

$0.23B

Treace Medical Concepts

$0.21B

Si-Bone

$0.20B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

LeMaitre Vascular

23.1%

Cerus

-6.7%

Si-Bone

-9.4%

OrthoPediatrics

-16.8%

Treace Medical Concepts

-27.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Cerus

26.7%

OrthoPediatrics

23.3%

Si-Bone

19.1%

LeMaitre Vascular

17.3%

Treace Medical Concepts

13.6%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Cerus leads the conversation

It holds 26.7% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $0.23B.

Price path

LeMaitre Vascular leads the available price paths

Its monthly-close return is +40.7% for the five-year window. At the other end, Treace Medical Concepts is -81.8% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

LeMaitre Vascular has the widest latest margin

Its FY2025 net margin is 23.1%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Cerus shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -530.0x while its five-year window price return is -57.8%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · KIDS

OrthoPediatrics

948available Prism news records

Prism top themes

Earnings & financial performance

Price action & investor response

Capital allocation & transactions

Legal, arbitration & regulatory

Leadership & governance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+19.7%146 latest 12m vs 122 prior 12m

Machine-classified coverage tone

77.5% positive-5.7 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

custom orthotics 18orthopedic specialty facility 16orthopedic hospital 16orthopedic surgery center 16earnings report 16orthopedic shoe insert 15orthopaedic center 14children's specialty hospital 11

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-25–2026-05-27 · trend and themes shown through 2026-05

Areas of research · CERS

Cerus

1,085available Prism news records

Prism top themes

Price action & investor response

Earnings & financial performance

Capital allocation & transactions

Leadership & governance

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-65.0%92 latest 12m vs 263 prior 12m

Machine-classified coverage tone

84.9% positive+2.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 19stock surge 17stock price 15share price 13earnings report 9initial public offering 8stock market debut 8ipo pricing 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-12 · trend and themes shown through 2026-06

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

KIDS

OrthoPediatrics

through 2026-05-01

Earnings releases 34M&A 1

2026-05-01
Earnings releases
Taking a closer look at the P&L, our 2026 worldwide revenue of $59.4 million increased 13% compared to 2025.
2025-02-14
M&A
Orthopediatrics unveils deal to buy Apifix to gain MID-C system
2026-01-12
Earnings releases
Generated preliminary unaudited fourth quarter 2025 net revenue of $61.3 million, representing 16% growth compared to $52.7 million in the fourth quarter of 2024.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LMAT

LeMaitre Vascular

through 2025-08-15

Earnings releases 12M&A 2Asset acquisitions 1Business contracts 1Listing / IPO 1

2025-08-15
Earnings releases
LeMaitre Vascular, Inc. recently reported second-quarter earnings, with sales reaching US$64.23 million and net income rising to US$13.78 million, both up from the prior year, and declared a quarterly dividend of US$0.20 per share payable in September 2025.
2025-05-02
Business contracts
Elutia Inc. (Nasdaq: ELUT) ("Elutia" or the "Company"), a pioneer in drug-eluting biomatrix products, today announced it is reclaiming U.S. sales and distribution responsibilities for its cardiovascular portfolio—including ProxiCor®, VasCure®, and Tyke®—following the conclusion of its distribution agreement with LeMaitre Vascular, Inc.
2025-02-14
Asset acquisitions
LeMaitre Vascular (Burlington, Massachusetts), a provider of peripheral vascular devices and implants, reported acquiring all the stock of Biomateriali (Milan, Italy), a privately held vascular graft manufacturer, for E1.8 million in cash, the assumption of E1.5 million to more than E2 million in liabilities.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

SIBN

Si-Bone

through 2026-01-12

Earnings releases 25Company announcements 1Listing / IPO 1

2026-01-12
Earnings releases
Worldwide revenue between $56.2 - $56.3 million, representing ~15% growth
2023-05-06
Company announcements
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, has announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of US$22.00.
2023-05-05
Listing / IPO
SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced the pricing of its underwritten public offering of 3,775,000 shares of its common stock at a price to the public of $22.00.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CERS

Cerus

through 2025-06-10

Earnings releases 2Listing / IPO 2Regulatory 1

2025-06-10
Earnings releases
Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cerus $185.14 million 1.49 -$37.49 million ($0.10) -14.40
2025-02-14
Listing / IPO
17 Cerus filed to sell up to $300M of common stock and debt in a shelf offering.
2023-06-05
Regulatory
Cerus received a $5-million cash milestone payment from BioOne triggered by the CE mark regulatory approval for its INTERCEPT Blood System for plasma in Europe.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TMCI

Treace Medical Concepts

through 2026-02-27

Earnings releases 22Leadership changes 4Lawsuits 2Listing / IPO 1

2026-02-27
Earnings releases
Generated revenue of $62.5 million in fourth quarter 2025 and revenue of $212.7 million for the full-year 2025
2025-05-21
Leadership changes
At the 2025 Annual Meeting of Stockholders held on May 20, 2025, Treace Medical Concepts, Inc. announced the election of Lawrence W. Hamilton and Deepti Jain as Class I directors for a three-year term.
2025-04-15
Lawsuits
The LAWSUIT: A class action securities lawsuit was filed against Treace Medical Concepts, Inc. (TMCI) that seeks to recover losses of Treace Medical Concepts, Inc. shareholders who were adversely affected by alleged securities fraud between May 8, 2023 and May 7, 2024

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence

2019 extracted base$10.20B–$11.75B

2025 extracted forecast$11.50B–$21.52B

Implied source CAGR7.4%

increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

84,236available Prism news records

Latest 12m volume+8.7%36648 vs 33721 records

Positive classified tone66.7%+5.2 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates

7,802

medical drama series

7,076

cannabis legalization trends & economic impact

6,207

recreational marijuana usage

5,579

in-flight medical emergency protocols

4,688

medical marijuana laws & regulatory frameworks

3,617

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 7,316marijuana legalization arguments 6,389weed decriminalization debates 6,068cannabis industry regulations 5,880legal cannabis sales 5,791non-medical cannabis consumption 5,551medical cannabis regulations 5,272state cannabis economies 5,173

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

cannabis legalization debates

7,802 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

6,624 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

uncertainty in reimbursements

7,008 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+8.7% news volume

The latest 12 months contain 36,648 matched records versus 33,721 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

66.7% positive · +5.2pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 21–28. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

OrthoPediatrics leads the readiness ranking

Its Prism readiness score is 52/100, the highest in this five-company comparison.

Open OrthoPediatrics in Companies Radar

Scale and margin leadership sit with LeMaitre Vascular and LeMaitre Vascular

LeMaitre Vascular has the largest displayed latest revenue at $0.25B; LeMaitre Vascular has the widest displayed latest margin at 23.1%.

Open LeMaitre Vascular in Companies Radar

Comparisons

Strongest versus weakest available price path

LeMaitre Vascular is +40.7% for its five-year window; Treace Medical Concepts is -81.8% for its five-year window.

Open LeMaitre Vascular in Companies Radar Open Treace Medical Concepts in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.25B for LeMaitre Vascular to $0.20B for Si-Bone. Entity and filing-period labels remain visible on the company cards.

Open LeMaitre Vascular in Companies Radar Open Si-Bone in Companies Radar

Anomalies

Cerus has the widest attention-readiness rank gap

It ranks #1 by measured news attention (26.7%) and #4 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Cerus in Companies Radar

OrthoPediatrics shows a price-operating divergence to inspect

Its displayed filing-revenue change is +141.1% while its available monthly-close return is -66.7%. The signs differ, but the two measures cover different windows and do not establish causality.

Open OrthoPediatrics in Companies Radar

Explanations

Attention measures coverage volume, not quality

Cerus's 26.7% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Cerus in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open OrthoPediatrics's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 52/100 score.

Open OrthoPediatrics in Companies Radar

Stress-test the largest divergence before forming a view

Compare OrthoPediatrics's profile with LeMaitre Vascular's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open OrthoPediatrics in Companies Radar Open LeMaitre Vascular in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.